XML 46 R59.htm IDEA: XBRL DOCUMENT v2.4.0.8
16. Segment Information (Details) (USD $)
 3 Months Ended 12 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Dec. 31, 2012
Segment Information        
Revenues $ 0 $ 0    
Cost of sales 0 0    
Gross margin 0 0    
Deprec. & Amort 478,104 8,687    
Segment profit (1,371,520) (2,092,612)    
Operating expenses 1,371,520 2,092,612    
Net loss from continuing ops. (1,380,175) (2,476,780)    
Preferred dividends $ 0 $ 124,375    
Net loss attributable to common shareholders (1,380,175) (2,601,155) (2,635,975) (7,366,061)
Assets 26,447,653   18,344,052  
Liabilities 10,694,773   8,878,318  
Bio Pharma [Member]
        
Segment Information        
Revenues         
Cost of sales         
Gross margin         
Deprec. & Amort 1,000      
Segment profit (1,000)      
Operating expenses 183,000      
Other expenses         
Impact of derivative securities         
Net loss from continuing ops. (184,000)      
Loss from discontinued ops.         
Preferred dividends         
Net loss attributable to common shareholders (184,000)      
Assets 230,000       
Liabilities 2,779,000       
ProElite [Member]
        
Segment Information        
Revenues          
Cost of sales          
Gross margin          
Deprec. & Amort          
Segment profit          
Operating expenses          
Other expenses         
Impact of derivative securities          
Net loss from continuing ops.          
Loss from discontinued ops.    (127,000)    
Preferred dividends          
Net loss attributable to common shareholders    (127,000)    
Assets 344,000 1,677,000    
Liabilities 625,000 1,998,000    
Other [Member]
        
Segment Information        
Revenues          
Cost of sales          
Gross margin          
Deprec. & Amort 477,000 9,000    
Segment profit (477,000) (9,000)    
Operating expenses 710,000 2,084,000    
Other expenses 5,000 20,000    
Impact of derivative securities    237,000    
Net loss from continuing ops. (1,192,000) (2,350,000)    
Loss from discontinued ops.          
Preferred dividends    $ 124    
Net loss attributable to common shareholders (1,192,000) (2,474,000)    
Assets 25,878,000 511,000    
Liabilities 7,291,000 19,927,000    
Total
        
Segment Information        
Revenues          
Cost of sales          
Gross margin          
Deprec. & Amort 478,000 9,000    
Segment profit (478,000) (9,000)    
Operating expenses 893,000 2,084,000    
Other expenses 5,000 20,000    
Impact of derivative securities    237,000    
Net loss from continuing ops. (1,376,000) (2,350,000)    
Loss from discontinued ops.    (127,000)    
Preferred dividends    $ 124    
Net loss attributable to common shareholders (1,376,000) (2,601,000)    
Assets 26,452,000 2,188,000    
Liabilities 10,695,000 21,925,000    
Stratus Rewards [Member]
        
Segment Information        
Revenues         
Cost of sales         
Gross margin         
Deprec. & Amort         
Segment profit         
Operating expenses         
Other expenses         
Impact of derivative securities         
Net loss from continuing ops.         
Loss from discontinued ops.         
Preferred dividends         
Net loss attributable to common shareholders